B of A Securities Upgrades Radius Health to Neutral, Announces $8 Price Target
B of A Securities analyst Greg Harrison upgrades Radius Health (NASDAQ:RDUS) from Underperform to Neutral and announces $8 price target.
Radius Health Expands Non-US Market Footprint For TYMLOS
Radius Health Expands Non-US Market Footprint for TYMLOS
Globalization has been a key priority for the Company over the past two years
Three additional market agreements now signed and executed:
- Labatec
Radius Health Gives Update On Abaloparatide Transdermal System
Radius Health Update on Abaloparatide Transdermal System
Company ascertained regulatory clarity for possible forward progression of abalo-TDS
Additional and successful clinical trial would be required to advance
Goldman Sachs Maintains Neutral on Radius Health, Lowers Price Target to $8
Goldman Sachs maintains Radius Health (NASDAQ:RDUS) with a Neutral and lowers the price target from $9 to $8.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
Radius Health (NASDAQ:RDUS) stock moved upwards by 18.8% to $6.94 during Thursday's after-market session. The company's market cap stands at $330.1 million.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.